BioNTech Has Agreed To Acquire Biotheus For $800M And Up To $150M In Potential Milestone Payments
BioNTech Has Agreed To Acquire Biotheus For $800M And Up To $150M In Potential Milestone Payments
biontech已同意以80000萬美元收購Biotheus，並最多支付15000萬美元的潛在里程碑款項
- Acquisition to support the global execution of BioNTech's oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody, with potential to replace current checkpoint inhibitor standard of care treatments for solid tumors
- With the acquisition of Biotheus, BioNTech aims to further strengthen its capabilities to develop, manufacture and commercialize next-generation bispecific antibodies and novel treatment combinations
- BioNTech and Biotheus plan to initiate multiple registrational trials with BNT327/PM8002 in late 2024 and 2025; further clinical trials evaluating BNT327/PM8002 as combination therapies are planned to start in 2024 and 2025
- BioNTech to pay $800 million to acquire 100 percent of the issued share capital and up to $150 million in potential milestone payments
- 收購旨在支持biontech的全球腫瘤策略的執行，併爲BNT327/PM8002提供完整的全球權利，這是一種正在研究中的PD-L1 x VEGF-A雙特異性抗體，有潛力取代當前對固性腫瘤標準治療的檢查點抑制劑。
- 通過收購Biotheus，biontech旨在進一步加強其開發、製造和商業化下一代雙特異性抗體和新穎治療組合的能力。
- biontech和Biotheus計劃在2024年底和2025年開始多個註冊試驗，評估BNT327/PM8002作爲聯合治療的進一步臨床試驗計劃於2024年和2025年開始。
- biontech將支付8千萬美元以收購已發行的全部股份，並最多支付15000萬美元的潛在里程碑付款。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間